Anlon Healthcare Limited – IPO
Anlon Healthcare Limited – IPO Details
| IPO Date | August 26, 2025 to August 29, 2025 |
| Listing Date | September 3, 2025 |
| Face Value | ₹ 10 / Share |
| Price Band | ₹ 86 to ₹ 91 / Share |
| Lot Size | 164 Shares |
| Total Issue Size | 1,33,00,000 shares (Aggregating up to ₹121.03 Cr) |
| Fresh Issue | |
| Offer for Sale | |
| Employee Discount | |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Share holding pre issue | 3,98,51,500 shares |
| Share holding post issue | 5,31,51,500 shares |
| Market Maker portion |
Anlon Healthcare Limited Timeline (Tentative Schedule)
Anlon Healthcare Limited IPO opens on August 26, 2025, and closes on August 29, 2025.
| IPO Open Date | August 26, 2025 |
| IPO Close Date | August 29, 2025 |
| Basis of Allotment | September 1, 2025 |
| Initiation of Refunds | September 2, 2025 |
| Credit of Shares to Demat | September 2, 2025 |
| Listing Date | September 3, 2025 |
| Cut-off time for UPI mandate confirmation | August 29, 2025 |
Anlon Healthcare Limited IPO Lot Size
Investors can bid for a minimum of 164 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Individual Investors (Retail) and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 164 | Rs.14,924 |
| Retail (Max) | 13 | 2,132 | Rs.194,012 |
| S-HNI (Min) | 14 | 2,296 | Rs.208,936 |
| S-HNI (Max) | 67 | 10,988 | Rs.999,908 |
| B-HNI (Min) | 68 | 11,152 | Rs.1,014,832 |
| HNI (Min) |
Anlon Healthcare Limited IPO Promoter Holding
| Share Holding Pre Issue | 70.26% |
| Share Holding Post Issue |
Anlon Healthcare Limited IPO Reservation
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| Anchor Investor Shares Offered | |
|
| Market Maker Shares Offered | |
|
| Other Shares Offered | |
|
| QIB Shares Offered | Not less than 75% |
|
| NII (HNI) Shares Offered | Not Less than 15% |
|
| bNII > ₹10L | |
|
| sNII < ₹10L | |
|
| Retail Shares Offered | Not more than 10% |
|
| Employee Shares Offered | |
|
| Total Shares Offered | |
Anlon Healthcare Limited IPO Anchor Investors Details
| Bid Date | |
| Shares Offered | |
| Anchor Portion Size (In Cr.) | |
| Anchor lock-in period end date for 50% shares (30 Days) | |
| Anchor lock-in period end date for remaining shares (90 Days) |
About Anlon Healthcare Limited
Incorporated in the year 2013, Anlon Healthcare Limited is a chemical manufacturing enterprise involved in the manufacturing of Pharma Intermediates and active pharmaceutical ingredients (APIs). The company produces high-purity pharmaceutical intermediates (to produce API) and active pharmaceutical ingredients (utilized for formulating medicines, nutraceuticals, personal care, and animal health products).
The company provides pharmaceutical intermediates, medicine APIs, nutraceuticals, personal care, and veterinary products, all processed according to Indian and international pharmacopeia standards such as IP, BP, EP, JP, and USP.
Apart from producing Pharma Intermediates and APIs according to global standards, the company is now engaged in custom manufacturing of complex chemicals beyond purity requirements and minimizing impurities to suit special customer requirements.
The firm has been granted Drug Master File (DMF) approval by ANVISA, NMPA, and PMDA for loxoprofen sodium dihydrate and loxoprofen acid APIs. The firm has submitted 21 DMFs with international authorities and is gearing up to file for approval of Ketoprofen and Dexketoprofen Trometamol.
The company maintains product quality by strictly testing, analyzing, and improving processes. Backed by four laboratories, the 34-strong team, comprising 24 science graduates, verifies products to customer and industry requirements.
The company has sixty-five (65) commercialized products and twenty-eight (28) products in pilot stage and forty-nine (49) products in laboratory test stage/ laboratory scale stage.
Products:
Pharma Intermediates:Cyanoethylbe nzoic acid, Ketonitrile and Methyldeslor atadine, these are a crucial starting material or an advance intermediate for production of APIs.
Active Pharmaceutical Ingredients: The APIs of the company are critical building blocks in pharmaceutical formulations, providing therapeutic action. They are formulated in products such as tablets, capsules, ointments, syrups, and in nutraceuticals, personal care, and veterinary products.
Competitive Strengths:
Strong product portfolio and scalable business.
Strong Promoters and Experienced Management Team.
High barriers to entry and exit because of long approval cycles of customers and stringent product requirements.
In-house Testing, Quality Control and Quality Assurance for quality control.
Quality, Environment, Health and Safety focus.
Key Performance Indicator
The market capitalization of Anlon Healthcare IPO is ₹483.68 Cr.
| KPI | Values |
|---|---|
| ROE | 40.45% |
| ROCE | 21.93% |
| Debt/Equity | 0.73 |
| RoNW | 25.51% |
| P/BV | 4.51 |
| PAT Margin (%) | 17.06% |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 5.15 | 3.86 |
| P/E (x) | 17.67 | 23.57 |
Note:
- The Pre IPO EPS is calculated based on Pre issue shareholding as on the date of RHP and the latest FY earnings as of March 31, 2025, that is available in RHP.
- The Post Issue EPS is calculated based on the Post issue shareholding and annualized FY earnings of March 31, 2025, which is available in RHP.
Objects of the Issue (Anlon Healthcare Limited IPO Objectives)
Anlon Healthcare Limited Contact Details
Anlon Healthcare Ltd. 101/102, Silvercoin Complex, Opp.Crystal Mall, Kalawad Road, Rajkot, Gujarat, 360005 Phone: +91 281 2562538 Email: [email protected] Website: http://www.anlon.in/ |
Anlon Healthcare Limited IPO Registrar
Kfin Technologies Ltd. Phone: 04067162222, 04079611000 Email: [email protected] Website: https://ipostatus.kfintech.com/ |